Revvity stock slipped about 3% to US$111.39 after its Q2 release, even though the headline numbers told a more upbeat story. Adjusted earnings per share of US$1.41 on roughly US$711 million of revenue, alongside higher full year guidance, landed well ahead of where expectations had been set.

The short term reaction reflects nerves around a rich P/E of 52.4x and a recent squeeze in net profit margin to 8.2%. The longer term debate is about whether that premium and margin pressure are justified by the earnings growth that analysts now project over the coming years.

Is Revvity’s 52.4x P/E a justified premium for 21.5% forecast earnings growth, or is the stock still priced for perfection despite softer 8.2% margins and a recent one off loss? Compare the current market price against detailed cash flow assumptions and peer multiples on our valuation analysis for Revvity

Q2 2026 Earnings Summary

• Revenue (Q2 2026 vs. Q2 2025): US$729.7 million vs. US$720.3 million (modest increase)
• Net Income (Excl. Extra Items, Q2 2026 vs. Q2 2025): US$53.5 million vs. US$55.2 million (slight decline)
• Basic EPS (Q2 2026 vs. Q2 2025): US$0.48 vs. US$0.47 (small improvement)
• Earnings from Discontinued Operations (Q2 2026 vs. Q2 2025): loss of US$1.7 million vs. loss of US$1.3 million (discontinued losses widened)

Tired of scrolling through dense earnings reports and trying to piece together what Revvity’s numbers really mean? Get a clear visual read on the company’s valuation in our company report for Revvity.

Evaluating Revvity’s Growth and Margins Bull Case

Bulls argue Revvity can use software, genomics and automation to lift growth and structurally improve margins. Q2 shows some concrete progress on that script. Organic revenue grew 3% and adjusted operating margin reached 29.3%, with free cash flow of US$184 million converting at 117% of adjusted net income. That supports the view that the model can generate cash while margins hold up.

The key software milestone is Signals. Despite a roughly 20% revenue decline in the quarter due to contract timing, Annual Recurring Revenue and Average Project Value are both growing at healthy double digit rates. That aligns with the bullish claim of a higher recurring software base, even if reported revenue is lumpy.

On the genomics and diagnostics side, Diagnostics organic growth of 11% and mid teens growth in reproductive health indicate that the newborn screening and genomics thesis is gaining traction.

Reveal where the surface looks calm but the multi year models for Revvity quietly diverge and see exactly where the consensus breaks on revenue, EPS and free cash flow in our analyst estimates for Revvity.

Revvity Bear Case: Growth Mix And Execution Still On Trial

The bearish view is that Revvity is too dependent on pressured end markets, exposed to China diagnostics risk and at risk of execution missteps as it pivots toward software and portfolio changes. Q2 does not fully clear that bar. Organic growth of 3% is still modest for a company leaning on secular themes, and Life Sciences revenue declined about 3% despite an improving pharma and biotech backdrop. That points to a growth mix that is not yet where bears would be forced to back off.

Signals is central to the software narrative, yet revenue declined about 20% in the quarter. Management attributes this to timing, with Annual Recurring Revenue and Average Project Value growing at double digit rates, but investors still lack a clean quarter that converts this momentum into reported top line. The China immunodiagnostics exit is signed rather than closed, so transition and execution risk remain live issues.

With Signals revenue timing, the China immunodiagnostics exit and one off items in recent results, it is worth asking whether these are isolated execution wrinkles or clues to deeper structural issues. Review the full risk analysis for Revvity which shows 1 important warning sign

Step Up Your Revvity Research

If Revvity’s rich P/E, margin pressure and mixed growth signals have your attention, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and wait for a setup that fits your plan. Once you own Revvity or other stocks, use the Portfolio Command Center to cut through noise and keep focus on the updates that actually matter to your thesis. For a broader perspective on Revvity and similar stocks, tap into the Community and see how other investors are thinking about the same risks and catalysts. This way you can spot potential turning points earlier, understand hidden risks in context and stay a step ahead of the market.

Seeking Alternatives Beyond Revvity Stock

Markets move fast and fresh opportunities will not wait. Scan curated ideas with real momentum before the crowd catches on and the best entry points are gone. Act now.

• Spot companies building long term compounding power and filter by balance sheet strength using the curated list of solid balance sheet and fundamentals stocks (49 results) before those stories stop flying under the radar.
• Track income plays with yields that could support your cash flow goals and lock in potential payout strength through the hand picked 7 dividend fortresses while the prices still look reasonable.
• Ride secular growth in automation and efficiency by reviewing carefully selected 36 robotics and automation stocks so you are not caught watching these opportunities from the sidelines later.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.